Filana Therapeutics Financials
This page shows Filana Therapeutics (FLNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Filana is still a cash-funded research effort, but FY2025 spending shifted away from R&D and toward overhead as liquidity tightened.
The most important change is not just lower cash burn but a different spending mix: R&D fell to$26.6M from$69.6M while SG&A stayed near$68.8M , so the company used much less cash even though it still reported a-$91.0M net loss. That gap between free cash flow of-$32.8M and the accounting loss means FY2025 looked less cash-hungry than the income statement alone would imply.
The balance sheet is still cash-backed, with
FY2024 financing cash was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Filana Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Filana Therapeutics carries a low D/E ratio of 0.59, meaning only $0.59 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.
Filana Therapeutics's current ratio of 2.23 indicates adequate short-term liquidity, earning a score of 41/100. The company can meet its near-term obligations, though with limited headroom.
Filana Therapeutics generates a -122.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -16.7% the prior year.
Filana Therapeutics passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Filana Therapeutics generates $0.35 in operating cash flow (-$32.3M OCF vs -$91.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Filana Therapeutics's EBITDA was -$94.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 32.7% from the prior year.
Filana Therapeutics reported -$91.0M in net income in fiscal year 2025. This represents a decrease of 273.7% from the prior year.
Filana Therapeutics earned $-1.88 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 28.8% from the prior year.
Cash & Balance Sheet
Filana Therapeutics generated -$32.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 71.9% from the prior year.
Filana Therapeutics held $95.5M in cash against $0 in long-term debt as of fiscal year 2025.
Filana Therapeutics had 48M shares outstanding in fiscal year 2025. This represents an increase of 0.2% from the prior year.
Margins & Returns
Filana Therapeutics's ROE was -122.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 105.6 percentage points from the prior year.
Capital Allocation
Filana Therapeutics invested $26.6M in research and development in fiscal year 2025. This represents a decrease of 61.8% from the prior year.
Filana Therapeutics invested $581K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 464.1% from the prior year.
FLNA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $4.0M-22.7% | $5.1M-62.6% | $13.7M | N/A | $17.7M+16.3% | $15.2M-6.4% | $16.2M |
| SG&A Expenses | N/A | $7.9M-80.4% | $40.3M+268.8% | $10.9M | N/A | $12.9M-72.0% | $46.2M+1148.4% | $3.7M |
| Operating Income | N/A | -$11.9M+73.9% | -$45.4M-84.6% | -$24.6M | N/A | -$30.6M+50.1% | -$61.4M-208.0% | -$19.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | N/A | -$10.8M+75.6% | -$44.2M-89.0% | -$23.4M | N/A | -$27.9M-554.0% | $6.2M-75.4% | $25.0M |
| EPS (Diluted) | N/A | $-0.22+76.1% | $-0.92-91.7% | $-0.48 | N/A | $-0.58-546.2% | $0.13+130.2% | $-0.43 |
FLNA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $118.4M-8.8% | $129.7M-4.2% | $135.4M-3.9% | $140.9M-10.5% | $157.5M-29.6% | $223.8M-8.1% | $243.6M+56.4% | $155.7M |
| Current Assets | $97.7M-10.3% | $108.9M-5.1% | $114.8M-4.4% | $120.2M-12.0% | $136.5M-32.6% | $202.5M-8.8% | $222.1M+65.8% | $134.0M |
| Cash & Equivalents | $95.5M-10.0% | $106.1M-5.6% | $112.4M-4.2% | $117.3M-8.7% | $128.6M-13.7% | $149.0M-28.1% | $207.3M+66.9% | $124.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $44.0M-8.7% | $48.2M+1.6% | $47.4M+256.0% | $13.3M+12.6% | $11.8M-79.3% | $57.1M+4.6% | $54.6M-29.2% | $77.1M |
| Current Liabilities | $43.8M-8.8% | $48.0M+1.5% | $47.3M+257.6% | $13.2M+12.7% | $11.8M-79.4% | $57.0M+4.5% | $54.6M-29.2% | $77.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $74.4M-8.8% | $81.6M-7.3% | $88.0M-31.1% | $127.6M-12.4% | $145.7M-12.6% | $166.6M-11.8% | $189.0M+140.4% | $78.6M |
| Retained Earnings | -$496.1M-2.6% | -$483.5M-2.3% | -$472.7M-10.3% | -$428.5M-5.8% | -$405.1M-7.3% | -$377.5M-8.0% | -$349.6M+1.7% | -$355.7M |
FLNA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.7M-56.7% | -$6.2M-25.8% | -$4.9M+56.4% | -$11.3M+81.5% | -$61.3M-234.9% | -$18.3M-0.3% | -$18.2M+4.6% | -$19.1M |
| Capital Expenditures | $501K+526.3% | $80K | $0 | $0-100.0% | $57K+235.3% | $17K-41.4% | $29K | $0 |
| Free Cash Flow | -$10.2M-62.7% | -$6.3M-27.4% | -$4.9M+56.4% | -$11.3M+81.5% | -$61.3M-234.9% | -$18.3M-0.2% | -$18.3M+4.5% | -$19.1M |
| Investing Cash Flow | -$501K-526.3% | -$80K | $0 | $0+100.0% | -$57K-235.3% | -$17K+41.4% | -$29K | $0 |
| Financing Cash Flow | -$329K | $0 | $0-100.0% | $90K-90.2% | $918K | $0-100.0% | $101.4M+357.5% | $22.2M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
FLNA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -13.3%+37.0pp | -50.3%-31.9pp | -18.3% | N/A | -16.8%-20.0pp | 3.3%-28.6pp | 31.9% |
| Return on Assets | N/A | -8.3%+24.3pp | -32.7%-16.1pp | -16.6% | N/A | -12.5%-15.0pp | 2.5%-13.6pp | 16.1% |
| Current Ratio | 2.23-0.0 | 2.27-0.2 | 2.43-6.7 | 9.08-2.5 | 11.62+8.1 | 3.55-0.5 | 4.07+2.3 | 1.74 |
| Debt-to-Equity | 0.590.0 | 0.59+0.1 | 0.54+0.4 | 0.10+0.0 | 0.08-0.3 | 0.34+0.1 | 0.29-0.7 | 0.98 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Frequently Asked Questions
Is Filana Therapeutics profitable?
No, Filana Therapeutics (FLNA) reported a net income of -$91.0M in fiscal year 2025.
What is Filana Therapeutics's EBITDA?
Filana Therapeutics (FLNA) had EBITDA of -$94.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Filana Therapeutics's return on equity (ROE)?
Filana Therapeutics (FLNA) has a return on equity of -122.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Filana Therapeutics's free cash flow?
Filana Therapeutics (FLNA) generated -$32.8M in free cash flow during fiscal year 2025. This represents a 71.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Filana Therapeutics's operating cash flow?
Filana Therapeutics (FLNA) generated -$32.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Filana Therapeutics's total assets?
Filana Therapeutics (FLNA) had $118.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Filana Therapeutics's capital expenditures?
Filana Therapeutics (FLNA) invested $581K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Filana Therapeutics spend on research and development?
Filana Therapeutics (FLNA) invested $26.6M in research and development during fiscal year 2025.
What is Filana Therapeutics's current ratio?
Filana Therapeutics (FLNA) had a current ratio of 2.23 as of fiscal year 2025, which is generally considered healthy.
What is Filana Therapeutics's debt-to-equity ratio?
Filana Therapeutics (FLNA) had a debt-to-equity ratio of 0.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Filana Therapeutics's return on assets (ROA)?
Filana Therapeutics (FLNA) had a return on assets of -76.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Filana Therapeutics's cash runway?
Based on fiscal year 2025 data, Filana Therapeutics (FLNA) had $95.5M in cash against an annual operating cash burn of $32.3M. This gives an estimated cash runway of approximately 36 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Filana Therapeutics's Piotroski F-Score?
Filana Therapeutics (FLNA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Filana Therapeutics's earnings high quality?
Filana Therapeutics (FLNA) has an earnings quality ratio of 0.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Filana Therapeutics?
Filana Therapeutics (FLNA) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.